Quest diagnostics fax number3/17/2023 The latest Quest Diagnostics analysis builds on two studies published by the company's medical team in JAMA Open Network in 20. Kaufman, MD, Senior Medical Director and Head of the Health Trends Research Program for Quest Diagnostics. And yet, our more recent analysis shows the pandemic, by delaying cancer diagnoses, is putting these gains at risk," said co-author Harvey W. "The decline in the cancer death rate over the past three decades is a major healthcare achievement. The study follows unaffiliated research by the American Association for Cancer Research (AACR) showing the death rate from cancer declined by 32% between 19, the year before the pandemic began, with gains "attributed mainly to the unprecedented progress against lung, colorectal, breast, and prostate cancer." A delayed cancer diagnosis can lead to more advanced disease, more aggressive and costly treatment, and worse outcomes. The findings suggest more people are living with undiagnosed cancers now than prior to the pandemic. While cancer diagnoses increased over the subsequent two years, the gains have not been enough to offset diagnoses delayed or missed earlier in the pandemic. The analysis found that cancer diagnoses plummeted by close to 30% in the first few months of the pandemic in 2020, when much of society and healthcare shut down. Based on 1,144,879 deidentified results of diagnostic tests by Quest Diagnostics between January 2018 and March 2022, the study is believed to be the largest to evaluate the association of the pandemic on cancer diagnoses, based on objective laboratory data, in the United States. Published today in the Journal of Clinical Oncology (JCO) Clinical Cancer Informatics, an American Society of Clinical Oncology (ASCO) journal, the study "New Cancer Diagnoses Still Lagging in United States in Second Full Year of COVID-19 Pandemic" analyzed rates of diagnoses of eight common types of cancer (prostate, breast, colorectal, lung, pancreatic, cervical, gastric and esophageal) of patients across the United States. SECAUCUS, N.J., October 17, 2022 /CSRwire/ - More than two years after the COVID-19 pandemic began, diagnoses of breast and prostate cancer, two of the nation's leading causes of cancer death, continue to lag behind pre-pandemic levels, according to a nationally representative Quest Diagnostics Health Trends® study by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |